KR20170100100A - A pharmaceutical composition comrprising Morus alba Linne extract for preventing or treating benign prostatic hyperplasia - Google Patents
A pharmaceutical composition comrprising Morus alba Linne extract for preventing or treating benign prostatic hyperplasia Download PDFInfo
- Publication number
- KR20170100100A KR20170100100A KR1020160022032A KR20160022032A KR20170100100A KR 20170100100 A KR20170100100 A KR 20170100100A KR 1020160022032 A KR1020160022032 A KR 1020160022032A KR 20160022032 A KR20160022032 A KR 20160022032A KR 20170100100 A KR20170100100 A KR 20170100100A
- Authority
- KR
- South Korea
- Prior art keywords
- extract
- prostatic hyperplasia
- present
- pharmaceutical composition
- preventing
- Prior art date
Links
- 239000000284 extract Substances 0.000 title claims abstract description 126
- 240000000249 Morus alba Species 0.000 title claims abstract description 34
- 235000008708 Morus alba Nutrition 0.000 title claims abstract description 34
- 206010004446 Benign prostatic hyperplasia Diseases 0.000 title claims abstract description 31
- 208000004403 Prostatic Hyperplasia Diseases 0.000 title claims abstract description 29
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 25
- 239000000203 mixture Substances 0.000 claims abstract description 62
- 238000000034 method Methods 0.000 claims abstract description 21
- 238000011282 treatment Methods 0.000 claims abstract description 18
- 230000002265 prevention Effects 0.000 claims abstract description 9
- 240000009138 Curcuma zedoaria Species 0.000 claims abstract description 8
- 235000003405 Curcuma zedoaria Nutrition 0.000 claims abstract description 8
- 239000004480 active ingredient Substances 0.000 claims description 17
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 15
- 239000002904 solvent Substances 0.000 claims description 13
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 9
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 9
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 9
- 238000000605 extraction Methods 0.000 claims description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 6
- 125000004432 carbon atom Chemical group C* 0.000 claims description 5
- 239000012046 mixed solvent Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 238000002137 ultrasound extraction Methods 0.000 claims description 4
- 238000011321 prophylaxis Methods 0.000 claims 2
- 244000291564 Allium cepa Species 0.000 claims 1
- 235000005255 Allium cepa Nutrition 0.000 claims 1
- 241000221017 Euphorbiaceae Species 0.000 claims 1
- 235000013305 food Nutrition 0.000 abstract description 28
- 239000003814 drug Substances 0.000 abstract description 20
- 230000000694 effects Effects 0.000 abstract description 20
- 229940079593 drug Drugs 0.000 abstract description 15
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 abstract description 9
- 229960004039 finasteride Drugs 0.000 abstract description 7
- 239000005445 natural material Substances 0.000 abstract 1
- 210000002307 prostate Anatomy 0.000 description 46
- 230000036541 health Effects 0.000 description 12
- 201000010099 disease Diseases 0.000 description 9
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 9
- 239000000047 product Substances 0.000 description 9
- 241001465754 Metazoa Species 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 240000006439 Aspergillus oryzae Species 0.000 description 6
- 235000002247 Aspergillus oryzae Nutrition 0.000 description 6
- 235000013361 beverage Nutrition 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 244000163122 Curcuma domestica Species 0.000 description 5
- 239000003795 chemical substances by application Substances 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 230000006872 improvement Effects 0.000 description 5
- 235000014375 Curcuma Nutrition 0.000 description 4
- 206010051482 Prostatomegaly Diseases 0.000 description 4
- 230000009471 action Effects 0.000 description 4
- 239000011651 chromium Substances 0.000 description 4
- VFLDPWHFBUODDF-FCXRPNKRSA-N curcumin Chemical compound C1=C(O)C(OC)=CC(\C=C\C(=O)CC(=O)\C=C\C=2C=C(OC)C(O)=CC=2)=C1 VFLDPWHFBUODDF-FCXRPNKRSA-N 0.000 description 4
- 235000013376 functional food Nutrition 0.000 description 4
- 239000011572 manganese Substances 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- 206010008479 Chest Pain Diseases 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- PWHULOQIROXLJO-UHFFFAOYSA-N Manganese Chemical compound [Mn] PWHULOQIROXLJO-UHFFFAOYSA-N 0.000 description 3
- PDMMFKSKQVNJMI-BLQWBTBKSA-N Testosterone propionate Chemical compound C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](OC(=O)CC)[C@@]1(C)CC2 PDMMFKSKQVNJMI-BLQWBTBKSA-N 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 150000001298 alcohols Chemical class 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 235000009508 confectionery Nutrition 0.000 description 3
- 235000003599 food sweetener Nutrition 0.000 description 3
- 238000005194 fractionation Methods 0.000 description 3
- 235000013402 health food Nutrition 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 229910052748 manganese Inorganic materials 0.000 description 3
- 231100000957 no side effect Toxicity 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003765 sweetening agent Substances 0.000 description 3
- 229960001712 testosterone propionate Drugs 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- NVKAWKQGWWIWPM-ABEVXSGRSA-N 17-β-hydroxy-5-α-Androstan-3-one Chemical compound C1C(=O)CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CC[C@H]21 NVKAWKQGWWIWPM-ABEVXSGRSA-N 0.000 description 2
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 2
- 229940113178 5 Alpha reductase inhibitor Drugs 0.000 description 2
- 239000002677 5-alpha reductase inhibitor Substances 0.000 description 2
- 206010006458 Bronchitis chronic Diseases 0.000 description 2
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 206010020772 Hypertension Diseases 0.000 description 2
- 206010020880 Hypertrophy Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 240000007049 Juglans regia Species 0.000 description 2
- 235000009496 Juglans regia Nutrition 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229920002230 Pectic acid Polymers 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- 206010057190 Respiratory tract infections Diseases 0.000 description 2
- 244000269722 Thea sinensis Species 0.000 description 2
- 230000002411 adverse Effects 0.000 description 2
- 239000000783 alginic acid Chemical class 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Chemical class 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 229960003473 androstanolone Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 239000011575 calcium Substances 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 229910052804 chromium Inorganic materials 0.000 description 2
- 208000007451 chronic bronchitis Diseases 0.000 description 2
- 239000003086 colorant Substances 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000010949 copper Substances 0.000 description 2
- 235000015872 dietary supplement Nutrition 0.000 description 2
- 239000003085 diluting agent Substances 0.000 description 2
- -1 etc.) Substances 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000000670 limiting effect Effects 0.000 description 2
- 239000011777 magnesium Substances 0.000 description 2
- 229940126601 medicinal product Drugs 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 239000010318 polygalacturonic acid Substances 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 239000008213 purified water Substances 0.000 description 2
- 235000019204 saccharin Nutrition 0.000 description 2
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 2
- 229940081974 saccharin Drugs 0.000 description 2
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 2
- YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 2
- 239000011734 sodium Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- LPXPTNMVRIOKMN-UHFFFAOYSA-M sodium nitrite Chemical compound [Na+].[O-]N=O LPXPTNMVRIOKMN-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 229940124597 therapeutic agent Drugs 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 210000003708 urethra Anatomy 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 235000020234 walnut Nutrition 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- CHHHXKFHOYLYRE-UHFFFAOYSA-M 2,4-Hexadienoic acid, potassium salt (1:1), (2E,4E)- Chemical compound [K+].CC=CC=CC([O-])=O CHHHXKFHOYLYRE-UHFFFAOYSA-M 0.000 description 1
- 206010000060 Abdominal distension Diseases 0.000 description 1
- 102000009027 Albumins Human genes 0.000 description 1
- 108010088751 Albumins Proteins 0.000 description 1
- 201000004384 Alopecia Diseases 0.000 description 1
- 201000000736 Amenorrhea Diseases 0.000 description 1
- 206010001928 Amenorrhoea Diseases 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241001149724 Cololabis adocetus Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000034656 Contusions Diseases 0.000 description 1
- 206010010904 Convulsion Diseases 0.000 description 1
- RYGMFSIKBFXOCR-UHFFFAOYSA-N Copper Chemical compound [Cu] RYGMFSIKBFXOCR-UHFFFAOYSA-N 0.000 description 1
- 241000186216 Corynebacterium Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 235000003392 Curcuma domestica Nutrition 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- FEWJPZIEWOKRBE-LWMBPPNESA-M D-tartrate(1-) Chemical compound OC(=O)[C@@H](O)[C@H](O)C([O-])=O FEWJPZIEWOKRBE-LWMBPPNESA-M 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 208000005171 Dysmenorrhea Diseases 0.000 description 1
- 206010013935 Dysmenorrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000010228 Erectile Dysfunction Diseases 0.000 description 1
- 239000004386 Erythritol Substances 0.000 description 1
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 1
- 208000007530 Essential hypertension Diseases 0.000 description 1
- 244000166124 Eucalyptus globulus Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 208000001953 Hypotension Diseases 0.000 description 1
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 1
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 240000004658 Medicago sativa Species 0.000 description 1
- 235000017587 Medicago sativa ssp. sativa Nutrition 0.000 description 1
- 241000218213 Morus <angiosperm> Species 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- 241000199919 Phaeophyceae Species 0.000 description 1
- 241001505935 Phalaenopsis Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 206010060862 Prostate cancer Diseases 0.000 description 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
- 229940123934 Reductase inhibitor Drugs 0.000 description 1
- 201000001880 Sexual dysfunction Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 239000004288 Sodium dehydroacetate Substances 0.000 description 1
- 244000228451 Stevia rebaudiana Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 1
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 231100000540 amenorrhea Toxicity 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 239000000022 bacteriostatic agent Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 235000021028 berry Nutrition 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000007844 bleaching agent Substances 0.000 description 1
- 208000024330 bloating Diseases 0.000 description 1
- 230000036772 blood pressure Effects 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 208000034526 bruise Diseases 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 235000019219 chocolate Nutrition 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 229910052802 copper Inorganic materials 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 235000003373 curcuma longa Nutrition 0.000 description 1
- 229940109275 cyclamate Drugs 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 201000006549 dyspepsia Diseases 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000008393 encapsulating agent Substances 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 235000019414 erythritol Nutrition 0.000 description 1
- 229940009714 erythritol Drugs 0.000 description 1
- 239000000469 ethanolic extract Substances 0.000 description 1
- 229940007062 eucalyptus extract Drugs 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 239000000835 fiber Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940014144 folate Drugs 0.000 description 1
- OVBPIULPVIDEAO-LBPRGKRZSA-N folic acid Chemical compound C=1N=C2NC(N)=NC(=O)C2=NC=1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 OVBPIULPVIDEAO-LBPRGKRZSA-N 0.000 description 1
- 235000019152 folic acid Nutrition 0.000 description 1
- 239000011724 folic acid Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000011194 food seasoning agent Nutrition 0.000 description 1
- 230000035784 germination Effects 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- 208000024963 hair loss Diseases 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 230000036543 hypotension Effects 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 201000001881 impotence Diseases 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 239000002917 insecticide Substances 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 150000002596 lactones Chemical class 0.000 description 1
- 239000012633 leachable Substances 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- VYQNWZOUAUKGHI-UHFFFAOYSA-N monobenzone Chemical compound C1=CC(O)=CC=C1OCC1=CC=CC=C1 VYQNWZOUAUKGHI-UHFFFAOYSA-N 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 239000002105 nanoparticle Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 235000021096 natural sweeteners Nutrition 0.000 description 1
- 210000005036 nerve Anatomy 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 239000012454 non-polar solvent Substances 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 1
- 239000002304 perfume Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000008196 pharmacological composition Substances 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 208000008423 pleurisy Diseases 0.000 description 1
- 239000002798 polar solvent Substances 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229940050271 potassium alum Drugs 0.000 description 1
- GNHOJBNSNUXZQA-UHFFFAOYSA-J potassium aluminium sulfate dodecahydrate Chemical compound O.O.O.O.O.O.O.O.O.O.O.O.[Al+3].[K+].[O-]S([O-])(=O)=O.[O-]S([O-])(=O)=O GNHOJBNSNUXZQA-UHFFFAOYSA-J 0.000 description 1
- 239000004302 potassium sorbate Substances 0.000 description 1
- 235000010241 potassium sorbate Nutrition 0.000 description 1
- 229940069338 potassium sorbate Drugs 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 229940117382 propecia Drugs 0.000 description 1
- 229940072254 proscar Drugs 0.000 description 1
- 201000004240 prostatic hypertrophy Diseases 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000012264 purified product Substances 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- HELXLJCILKEWJH-NCGAPWICSA-N rebaudioside A Chemical compound O([C@H]1[C@H](O)[C@@H](CO)O[C@H]([C@@H]1O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)O[C@]12C(=C)C[C@@]3(C1)CC[C@@H]1[C@@](C)(CCC[C@]1([C@@H]3CC2)C)C(=O)O[C@H]1[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O1)O)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O HELXLJCILKEWJH-NCGAPWICSA-N 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960004889 salicylic acid Drugs 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000035946 sexual desire Effects 0.000 description 1
- 231100000872 sexual dysfunction Toxicity 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 229960003885 sodium benzoate Drugs 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 235000019259 sodium dehydroacetate Nutrition 0.000 description 1
- 229940079839 sodium dehydroacetate Drugs 0.000 description 1
- 235000010288 sodium nitrite Nutrition 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- DSOWAKKSGYUMTF-GZOLSCHFSA-M sodium;(1e)-1-(6-methyl-2,4-dioxopyran-3-ylidene)ethanolate Chemical compound [Na+].C\C([O-])=C1/C(=O)OC(C)=CC1=O DSOWAKKSGYUMTF-GZOLSCHFSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000013599 spices Nutrition 0.000 description 1
- 238000012453 sprague-dawley rat model Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000002889 sympathetic effect Effects 0.000 description 1
- 230000001975 sympathomimetic effect Effects 0.000 description 1
- JBQYATWDVHIOAR-UHFFFAOYSA-N tellanylidenegermanium Chemical compound [Te]=[Ge] JBQYATWDVHIOAR-UHFFFAOYSA-N 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 235000013976 turmeric Nutrition 0.000 description 1
- 230000002485 urinary effect Effects 0.000 description 1
- 239000004474 valine Substances 0.000 description 1
- MWOOGOJBHIARFG-UHFFFAOYSA-N vanillin Chemical compound COC1=CC(C=O)=CC=C1O MWOOGOJBHIARFG-UHFFFAOYSA-N 0.000 description 1
- FGQOOHJZONJGDT-UHFFFAOYSA-N vanillin Natural products COC1=CC(O)=CC(C=O)=C1 FGQOOHJZONJGDT-UHFFFAOYSA-N 0.000 description 1
- 235000012141 vanillin Nutrition 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- 235000019155 vitamin A Nutrition 0.000 description 1
- 239000011719 vitamin A Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 239000013585 weight reducing agent Substances 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
- A61K36/605—Morus (mulberry)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2300/00—Processes
- A23V2300/48—Ultrasonic treatment
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Botany (AREA)
- Mycology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Alternative & Traditional Medicine (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
Description
The present invention relates to a composition comprising Morus alba Linne) Extract and Curcuma The present invention relates to a composition for preventing or treating enlargement of the prostate gland, comprising the extract of Wang Bai Bai , a fraction thereof, an extract or its fractions as an active ingredient, a composition for preventing or treating prostate enlargement, , A quasi-drug composition, and a method of preventing or treating enlargement of the prostate using the pharmaceutical composition.
Prostate enlargement is a benign tumor commonly seen in middle-aged men in their 40s and 50s. The prostate enlarges, pushes the posterior urethra, increases resistance to urinary flow, and results in difficulty in urinating. It is one of the most common diseases occurring in middle-aged men and usually starts in their 40s, 50% of their fifties, 60% of their 60s and 70% of their 70s have enlarged prostates. As the elderly population increases, Of the total population.
In order to treat the enlargement of the prostate, sympathetic blockers for relieving the tension of the smooth muscle of the prostate gland, an anti-male hormone agent for inhibiting the abnormal proliferation of the prostate gland epithelium, and a 5α-reductase inhibitor, It has been used for preventive purposes. However, sympathomimetic blockers lower blood pressure, so they are limited in patients with hypotension. In the process of artificially controlling the nerves, bowel movements may be reduced to cause constipation or chronic fatigue. In addition, anti-male hormone agents may cause side effects such as loss of sexual desire, erectile dysfunction, and the like.
Finasteride is a representative 5a-reductase inhibitor, marketed under the trade name Proscar or Propecia. Finasteride inhibits the production of DHT (Dihydrotestosterone), which reduces the activity of the prostate in the prostate and reduces the prostate weight and volume, thereby inhibiting the progression to benign prostatic hyperplasia and reducing the risk of developing prostate cancer (Robaire B et al., 2006, Molecular and Cellular Endocrinology, 250 (1-2): 190-5).
Due to the superiority of such effects, the development of related art using a pinastellite such as a novel production method of high-purity pinasteride (Korean Patent No. 0483136) and a composition for treating hair loss including polymerized pinasteride nanoparticles (Korea Patent Publication No. 2015-0046332) . However, the adverse effects of increasing the incidence of breast cancer in men and causing sexual dysfunction have been reported and require caution in use (Medlaines and Healthcare products Regulatory Agency Drug Safety Update, 2009; Mella JM et al., 2010), Archives of Dermatology 146 (10): 1141-50.).
On the other hand, Mori Cortex (Morus alba Linne) is a medicinal product made from the root bark of the mulberry tree or the mulberry tree of the mulberry tree. It is known to be effective for the chronic seizures of chronic bronchitis, chest pain after healing of pneumonia, bloating of chest pain caused by leaching of cough or leachable pleurisy, It has also proved effective as a therapeutic agent for arteriosclerotic hypertension and essential hypertension. In addition, although it has been known that ethanol extract of bark saponin can be used for the treatment of depression (Korea Patent Publication No. 2009-0116547), the effect on benign prostatic hyperplasia has not been disclosed.
Under these circumstances, the inventors of the present invention have made extensive efforts to develop a therapeutic agent for benign prostatic hyperplasia with no side effects, and as a result, it has been found that a composition containing the extract of Mulberry bark extract, which is a natural herb, has excellent effects on benign prostatic hyperplasia Respectively.
One object of the present invention are Mori Cortex (Morus alba Linne extract or fractions thereof as an active ingredient. The present invention also provides a pharmaceutical composition for preventing or treating enlargement of the prostate.
It is another object of the present invention to provide a method for preventing or treating enlargement of the prostate gland, which comprises administering the pharmaceutical composition to a subject other than a human.
It is still another object of the present invention to provide a food composition for preventing or ameliorating enlargement of the prostate gland, which comprises the extract of Walnut or the fraction thereof as an active ingredient.
It is still another object of the present invention to provide a quasi-drug composition for preventing or ameliorating the enlargement of the prostate gland, which comprises extracts of Eucalyptus or its fractions as an active ingredient.
One aspect of the present invention for achieving the above object is to provide a method for producing an oil- alba Linne extract or a fraction thereof as an active ingredient. The present invention also provides a pharmaceutical composition for preventing or treating enlargement of the prostate gland.
In the present invention, it has been confirmed that the mixture of the extract of Mulberry bark extract and the extract of the extract of Mulberry bark extract effectively reduces the weight of the prostate gland of the test animal in which the enlargement of the prostate gland has been induced, It can be used as an active ingredient.
The term " Morus " alba Linne "refers to a medicinal product made from the root bark of the mulberry tree of the mulberry tree or the root of the same plant. Generally, the root is taken off from the late autumn to the next spring until the germination is carried out, the surface is crushed, It is known that there is a slight peculiar odor and almost no taste. The above-mentioned bark is known to be effective for chest pain caused by chronic bronchitis, coronary artery sclerosis hypertension, etc. However, the therapeutic effect of prostate-related diseases is unknown, .
The above-mentioned canopy can be purchased commercially, sold or cultivated in nature.
The term "extract" of the present invention is intended to mean an extract obtained by extracting the above-mentioned phaeophyta, a diluted solution or concentrate of the extract, a dried product obtained by drying the extract, a controlled preparation or a purified product of the extracted solution, And extracts of all formulations which can be formed using extracts.
There is no particular limitation on the method for extracting the alfalfa extract, and extraction can be carried out according to a method commonly used in the art. Non-limiting examples of the extraction method include hydrothermal extraction, ultrasonic extraction, filtration, and reflux extraction. These may be performed alone or in combination with two or more methods.
In the present invention, the type of the extraction solvent used for extracting the above-mentioned saury is not particularly limited, and any solvent known in the art can be used. Nonlimiting examples of the extraction solvent include water, alcohols having 1 to 4 carbon atoms, and mixed solvents thereof. These solvents may be used alone or in combination. Specific 70% ethanol may be used, but is not limited thereto.
The term "fraction " of the present invention means a product obtained by performing fractionation to separate a specific component or a specific component group from a mixture containing various components.
The fractionation method for obtaining the fraction in the present invention is not particularly limited and may be carried out according to a method commonly used in the art. As a non-limiting example of the above-mentioned fractionation method, there can be mentioned a method in which a fraction obtained from the extract is treated with a predetermined solvent by extracting the extract obtained from the extract of Morus alba L. of the present invention.
The kind of the fraction solvent used for obtaining the fraction in the present invention is not particularly limited, and any solvent known in the art can be used. Non-limiting examples of the fraction solvent include polar solvents such as water and alcohols having 1 to 4 carbon atoms; Non-polar solvents such as hexane, ethyl acetate, chloroform and dichloromethane; Or a mixed solvent thereof. These may be used alone or in combination of one or more, but the present invention is not limited thereto.
In addition, the extract or fraction may be prepared and used in the form of a dry powder after extraction, but is not limited thereto.
The term "hyperplasia of the prostate" of the present invention refers to a disease that makes the urethra difficult to urinate when the prostate enlarges abnormally, and when the size of the prostate enlarges, the prostate enlargement is diagnosed. Prostate hyperplasia is one of the most common diseases that occur in middle-aged men. It usually starts in the forties, and 50% of the 50s, 60% of the 60s and 70% of the 70s are known to have the disease.
The pharmaceutical composition for preventing or treating enlargement of the prostate of the present invention may further comprise an extract or its fraction as an active ingredient.
The term " Curcuma " zedoaria) "are turmeric (Curcuma zedoaria Rosc.). < / RTI > It is 2 ~ 8cm in length and 1.5 ~ 4cm in diameter. It shows an outer shape of oval shape, long circular shape, conical shape or long fusiform shape. There is a slight peculiar smell, and the taste is known to be a little bit spicy. Amenorrhea, dysmenorrhea, dyspepsia, bruise, etc. However, the therapeutic effect of the prostate-related diseases is not known, and it was firstly described by the present inventors.
The outlets may be purchased commercially, sold in nature or cultivated.
The term "prophylactic" of the present invention encompasses all or part of the action of inhibiting or delaying prostatic hyperplasia by administration of a pharmaceutical composition of the present invention, further comprising an extract or extract thereof or fraction thereof, it means.
The term "treatment" of the present invention refers to any action that improves or alters the prostatic hyperplasia by the administration of the pharmaceutical composition.
In a specific example of the present invention, it was confirmed that the weight of the prostate gland of the experimental animals in which the enlargement of the prostate gland was induced was reduced when the mixture of the extract of Manganese bark extract, the extract of Aspergillus oryzae, And Fig. 1). This suggests that the extract of the present invention or a mixture of the extracts can be used as an active ingredient in the treatment of benign prostatic hyperplasia.
The pharmaceutical composition of the present invention may contain 0.0001 to 50% by weight of the extract of Mulberry, more specifically 0.01 to 10% by weight, based on the weight of the total composition, but is not limited thereto.
The extract may contain 0.0001 to 50% by weight, specifically 0.01 to 10% by weight, but is not limited thereto.
The pharmaceutical composition of the present invention may contain the extract of Mulberry and its extracts at a weight ratio of 0.001 to 5: 0.001 to 5, more specifically 0.001 to 3: 0.001 to 3, more specifically 1: 1, but is not limited thereto.
The pharmaceutical composition of the present invention may comprise a mixture of extracts of the extract alone or extracts alone, and may also contain extracts of a mixture of the extracts of the extracts with the extracts of the extracts of corn syrups and extracts, , But is not limited thereto.
The pharmaceutical compositions of the present invention may further comprise pharmaceutically acceptable carriers, excipients or diluents conventionally used in the manufacture of pharmaceutical compositions, which may include non-naturally occuring carriers have.
The pharmaceutical compositions may be formulated in the form of powders, granules, tablets, capsules, suspensions, emulsions, syrups, aerosols and the like, oral preparations, suppositories and sterilized injection solutions according to conventional methods.
The term "pharmaceutically acceptable" of the present invention means to exhibit no toxicity to cells or humans exposed to the composition.
Specifically, the type of the carrier is not particularly limited, and any carrier conventionally used in the art and pharmaceutically acceptable may be used. Examples of the carrier include, but are not limited to, saline, sterilized water, Ringer's solution, buffered saline, albumin injection solution, dextrose solution, maltodextrin solution, glycerol and ethanol. These may be used alone or in combination of two or more. In addition, if necessary, other conventional additives such as an antioxidant, a buffer and / or a bacteriostatic agent can be added and used. A diluent, a dispersant, a surfactant, a binder, a lubricant, Pills, capsules, granules or tablets, and the like.
The mode of administration of the pharmaceutical composition for the prophylactic or therapeutic treatment of benign prostatic hyperplasia according to the present invention is not particularly limited and may be conventionally used in the art. As a non-limiting example of such a mode of administration, the compositions may be administered orally or parenterally. Further, the composition for preventing, ameliorating or treating the enlargement of the prostate of the present invention may be manufactured into various formulations depending on the intended administration mode.
Another aspect provides a method of preventing or treating hyperplasia of the prostate, comprising administering the pharmaceutical composition to an individual other than a human.
At this time, the definition of the enlargement of the prostate, prevention and treatment is as described above.
The term "administering" of the present invention means introducing the desired substance into the subject in a suitable manner.
The term "individual" of the present invention means all animals including mice, mice, livestock and the like, including humans who have developed or may develop prostate enlargement. As a specific example, it may be a mammal including a human.
Specifically, the method for preventing or treating enlargement of the prostate of the present invention comprises administering to a subject other than a human, a pharmacologically effective amount of a pharmacological composition comprising an extract of Mulberry bark extract or a fraction thereof and further comprising an extract or a fraction thereof Step < / RTI >
The term "pharmaceutically effective amount" of the present invention means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment and not causing side effects, Including, but not limited to, age, weight, health status, type of disease, severity, activity of the drug, sensitivity to the drug, method of administration, time of administration, route of administration and rate of release, And can be readily determined by those skilled in the art according to factors well known in the art.
The composition of the present invention may be administered at a dose of 0.0001 to 100 mg / kg body weight per day, more specifically 0.001 to 100 mg / kg body weight, based on the solid content. The administration may be such that the recommended dose is administered once a day or divided into several doses.
In the method for preventing or treating enlargement of the prostate gland according to the present invention, the administration route and method of administering the composition are not particularly limited, and any route of administration may be used as long as the composition containing the composition can reach the desired site Depending on the mode of administration. Specifically, the composition may be administered orally or parenterally through various routes. Non-limiting examples of routes of administration include oral, rectal, topical, intravenous, intraperitoneal, intramuscular, intraarterial, transdermal, Intramuscularly or through inhalation or the like.
Another aspect provides a food composition for preventing or ameliorating enlargement of the prostate gland, which comprises the extract of Walnut or a fraction thereof as an active ingredient.
At this time, the definitions of the above-mentioned extracts, fractions, prostatic hyperplasia and prevention are as described above.
The food composition for preventing or ameliorating the enlarged prostate of the present invention comprises the extract of the bodom or bark extract or the fraction thereof, and the extract or the fraction thereof may further comprise an active ingredient.
The term "improvement" of the present invention means any action that at least reduces the degree of symptom associated with the condition being treated by administration of the composition of the present invention.
The term "food" of the present invention includes dairy products such as meat, sausage, bread, chocolate, candy, snacks, confectionery, pizza, ramen and other noodles, gums, ice cream, various soups, drinks, tea, , A vitamin complex, a health functional food, and a health food, all of which include foods in a conventional sense.
Since the food composition of the present invention can be routinely ingested, a high prostate enlargement improvement effect can be expected, and thus it can be very usefully used for health promotion purposes.
The term "functional food" as used herein means the same term as "food for special health use" (FoSHU). In addition to nutrition, It means food. Here, 'function (surname)' refers to the structure and function of the human body to obtain a beneficial effect for health use such as controlling nutrients or physiological action. The food of the present invention can be prepared by a method commonly used in the art and can be prepared by adding raw materials and ingredients which are conventionally added in the art. In addition, the above-mentioned food formulations can be manufactured without limitations as long as they are formulations recognized as food. The composition for food of the present invention can be manufactured in various formulations, and unlike general pharmaceuticals, it has an advantage that there is no side effect that may occur when a food is used as a raw material for a long period of taking a medicine, The food of the invention can be taken as an adjuvant to improve the prostatic hyperplasia improving effect.
The health food refers to a food having an active health promotion or promotion effect compared with a general food, and a health supplement food refers to a food for health assistance. In some cases, the terms health functional foods, health foods, and health supplements are used.
Specifically, the health functional food is a food prepared by adding the compound of the present invention to a food material such as a beverage, a tea, a spice, a gum, confectionery, or the like, or encapsulated, powdered or suspended therein. But it has the advantage that there is no side effect that can occur when the food is used as a raw material and long-term use of the drug.
The food composition may further comprise a physiologically acceptable carrier. The type of carrier is not particularly limited, and any carrier conventionally used in the art can be used.
In addition, the food composition may contain additional components that are commonly used in food compositions and can improve odor, taste, visual appearance, and the like. For example, vitamins A, C, D, E, B1, B2, B6, B12, niacin, biotin, folate, panthotenic acid and the like. Minerals such as zinc (Zn), iron (Fe), calcium (Ca), chromium (Cr), magnesium (Mg), manganese (Mn), copper (Cu) and chromium (Cr); And amino acids such as lysine, tryptophan, cysteine, valine, and the like.
In addition, the food composition may further contain antiseptic agents (such as potassium sorbate, sodium benzoate, salicylic acid, sodium dehydroacetate), bactericides (Sodium nitrite), bleach (sodium sulfite), seasoning (sodium MSG glutamate, etc.), sweeteners (dicin, cyclamate, saccharin, etc.), coloring agents , Sodium, etc.), perfume (vanillin, lactones, etc.), swelling agents (alum, potassium hydrogen D-tartrate), emulsifiers, thickeners (foams), encapsulating agents, gum bases, foam inhibitors, solvents, And may include food additives. The additives may be selected and used in appropriate amounts depending on the type of food.
As an example of the food composition of the present invention, it can be used as a health beverage composition. In this case, various flavors or natural carbohydrates can be added as an additional ingredient like ordinary beverages. The above-mentioned natural carbohydrates include monosaccharides such as glucose and fructose; Disaccharides such as maltose, sucrose; Polysaccharides such as dextrin, cyclodextrin; Xylitol, sorbitol, erythritol, and the like. Sweeteners include natural sweeteners such as tau Martin and stevia extract; Synthetic sweetening agents such as saccharin and aspartame, and the like can be used. The ratio of the natural carbohydrate may be generally about 0.01 to 0.04 g, specifically about 0.02 to 0.03 g per 100 mL of the health beverage composition of the present invention.
In addition to the above, the health beverage composition may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acid, salts of pectic acid, alginic acid, salts of alginic acid, organic acid, protective colloid thickener, pH adjuster, stabilizer, Alcohols or carbonating agents, and the like. It may also contain flesh for the production of natural fruit juices, fruit juice drinks, or vegetable drinks. These components may be used independently or in combination. The proportion of such additives is not critical, but is generally selected in the range of 0.01 to 0.1 parts by weight per 100 parts by weight of the health beverage composition of the present invention.
Another aspect provides a quasi-drug composition for preventing or ameliorating the enlargement of the prostate gland, comprising the extract of W. bark or a fraction thereof as an active ingredient.
Herein, the definitions of the above-mentioned extracts, fractions, prostatic hyperplasia, prevention and improvement are as described above.
The quasi-drug composition for preventing or ameliorating the enlargement of the prostate of the present invention comprises the extract of Wu-bai berry extract or its fraction, and the extract or its fraction may further contain as an active ingredient.
The term "quasi-drug" of the present invention means a fiber, a rubber product or the like used for treating, alleviating, treating or preventing a disease of a human or an animal, Or products similar to those that are not machinery, preparations used for sterilization, insecticides and similar uses for the prevention of infectious diseases, for the purpose of diagnosis, treatment, alleviation, treatment or prevention of diseases of human or animal Means an article, except machinery, machinery or equipment, of the commodity used, and not used for the purpose of giving pharmacological effects to the structure and function of humans or animals; In addition, the quasi-drug may include external preparations for skin and personal hygiene products.
When the extract according to the present invention or a fraction thereof is used as a quasi-drug additive, the extract or the fraction thereof can be used as it is or can be used in combination with other quasi-drugs or quasi-drugs, and can be suitably used according to a conventional method. The amount of the active ingredient to be mixed can be appropriately determined depending on the purpose of use.
The external preparation for skin may be prepared and used in the form of, for example, an ointment, a lotion, a spray, a patch, a cream, a powder, a suspension, a gel or a gel.
The quasi-drug composition of the present invention may be contained in various weight percentages as long as it can prevent or improve enlargement of the prostate gland. Specifically, the extract or fraction thereof of the present invention may be contained in an amount of 0.01 to 100% by weight, 1 to 80% by weight.
The composition comprising the extract of Corynebacterium phalaenopsis, the extract of Aspergillus oryzae, the extract of Aspergillus oryzae and the extract of Aspergillus oryzae as an active ingredient may be used for the treatment of benign prostatic hyperplasia similar to or better than that of finasteride used as an agent for prostatic hypertrophy Prevention, improvement, and cure.
In addition, since the composition of the present invention is derived from a natural product, it can be safely used without any adverse effect on prevention, treatment and improvement of enlarged prostate.
FIG. 1 is a graph showing the prostate weight reduction effect of each extract according to the present invention. FIG. NC means normal control, BPH means benign prostatic hyperplasia, and Finasteride treatment was used as positive control. All values are expressed as mean ± SEM. The statistical significance of each result was confirmed by the ANOVA test, and the different subscripts denoted by a, b, c, or d indicate a significant difference at p <0.01.
Hereinafter, the present invention will be described in more detail with reference to the following examples. However, the following examples are intended to illustrate the present invention, but the scope of the present invention is not limited thereto.
Manufacturing example 1. Preparation of extract
Manufacturing example 1-1. Production of Eucalyptus extract
Morus alba (Scientific name: Morus alba Linne, Mori Radicis Cortex) was prepared as follows. Commercially available cornflakes were obtained and pulverized, and then 10 L of 70% ethanol was added to 1 kg of the pulverized product. Then, ultrasonic extraction was performed three times for 1 hour by using an ultrasonic wave extractor. The supernatant extract was filtered with Advantec No. 2 (110 mm) filter paper to remove insoluble matter, and then concentrated under reduced pressure at 45 ° C with a condenser equipped with a cooling condenser. To completely remove the solvent of the concentrated extract, 100 mL of purified water was added to suspend it, and 146.4 g of the extract was obtained using a freeze dryer (yield: 14.6%).
Manufacturing example 1-2. Out Preparation of extract
Curcuma (Scientific name: Curcuma) zedoaria , product name: Curcumae Rhizoma) was prepared by the following method. Commercially available outlets were obtained and pulverized, and then 10 L of 70% ethanol was added to 1 kg of the pulverized product. Then, ultrasonic extraction was performed three times for 1 hour by using an ultrasonic wave extractor. The supernatant extract was filtered with Advantec No. 2 (110 mm) filter paper to remove insoluble matter, and then concentrated under reduced pressure at 45 ° C with a condenser equipped with a cooling condenser. To completely remove the solvent of the concentrated extract, 500 mL of purified water was added to suspend the suspension, and 41.43 g of an extract was obtained (yield: 4.14%) using a freeze dryer.
Example 1. The prostate of the extract Effect on hypertrophy analysis
Example 1-1. Measuring prostate weight
Since the weight gain of the prostate gland is one of the major symptoms of enlarged prostate gland, the following experiment was conducted to analyze the effect of each extract on enlargement of the prostate gland.
Male SD rats (Sprague-Dawley rats, Orient Bio) 200 to 220 g were purged for one week, and then 6 rats per group were used for the experiment.
Control group with hypertrophy of prostate was prepared by subcutaneously injecting 10 ㎎ / ㎏ of TP (testosterone propionate) for 4 weeks.
The experimental group treated with each extract was prepared by orally administering the mixture of the extract of Mulberry, Mulberry Extract, or the mixture of Mulberry and Mulberry (1: 1) prepared in Example 1 at 100 mg / kg for 4 weeks before TP injection . The mixture was prepared by mixing the extracts of the extracts and the extracts with a solvent immediately before administration.
A positive control group treated with finasteride, a 5α-reductase inhibitor used as a treatment for benign prostatic hyperplasia, was prepared by orally administering pinasteride at 10 mg / kg.
In normal control, corn oil was injected subcutaneously.
The prostate weights of the experimental animals according to the treatment of each extract are summarized in Table 1 below.
As a result, as shown in Table 1 and FIG. 1, when the mixture of the extract of Manganese Bark extract, the extract of Aspergillus oryzae, and the extract of Aspergillus oryzae was treated with the test animal, the weight of the test animal Respectively. In addition, it was confirmed that this effect is similar to or better than that of Finasteride, which is used as a medicine for prostatic hyperplasia.
In addition, it was confirmed that the mixture of Ewha womans 'extract and Auckwheat extract had a better effect of reducing the prostate weight than that of the extract of Ewha Womans' extract or Awaku extract alone.
From the above results, it can be seen that the extract or the mixture of the extract of the present invention can be effectively used for the treatment of benign prostatic hyperplasia.
From the above description, it will be understood by those skilled in the art that the present invention may be embodied in other specific forms without departing from the spirit or essential characteristics thereof. In this regard, it should be understood that the above-described embodiments are to be considered in all respects as illustrative and not restrictive. The scope of the present invention should be construed as being included in the scope of the present invention without departing from the scope of the present invention as defined by the appended claims.
Claims (10)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160022032A KR102043404B1 (en) | 2016-02-24 | 2016-02-24 | A pharmaceutical composition comrprising Morus alba Linne extract for preventing or treating benign prostatic hyperplasia |
| PCT/KR2017/002001 WO2017146486A1 (en) | 2016-02-24 | 2017-02-23 | Composition for preventing or treating benign prostatic hyperplasia, containing morus alba linne extract |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR1020160022032A KR102043404B1 (en) | 2016-02-24 | 2016-02-24 | A pharmaceutical composition comrprising Morus alba Linne extract for preventing or treating benign prostatic hyperplasia |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20170100100A true KR20170100100A (en) | 2017-09-04 |
| KR102043404B1 KR102043404B1 (en) | 2019-11-12 |
Family
ID=59685383
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020160022032A KR102043404B1 (en) | 2016-02-24 | 2016-02-24 | A pharmaceutical composition comrprising Morus alba Linne extract for preventing or treating benign prostatic hyperplasia |
Country Status (2)
| Country | Link |
|---|---|
| KR (1) | KR102043404B1 (en) |
| WO (1) | WO2017146486A1 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102018213227A1 (en) | 2017-08-08 | 2019-02-14 | Mando Corporation | Piston pump for brake system |
| KR20190090910A (en) | 2018-01-26 | 2019-08-05 | 최윤식 | Compositions for improvement benign prostatic hyperplasia comprising bee pollen |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102211313B1 (en) | 2019-01-17 | 2021-02-04 | 경희대학교 산학협력단 | A composition for preventing or treating prostatic hyperplasia comprising a mixed extract of Curcumae Radix and Syzygii Flos |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1259905C (en) * | 2003-08-05 | 2006-06-21 | 北京大学 | Use of Rhizoma-Curcumae-Longae element in preparing medicine for treating lung disease |
| KR101515533B1 (en) * | 2013-06-21 | 2015-04-29 | 고려대학교 산학협력단 | Composition Containing the Morus Alba Root Extract for Lowering Blood Cholesterol Levels |
-
2016
- 2016-02-24 KR KR1020160022032A patent/KR102043404B1/en active IP Right Grant
-
2017
- 2017-02-23 WO PCT/KR2017/002001 patent/WO2017146486A1/en active Application Filing
Non-Patent Citations (4)
| Title |
|---|
| Arch. Pharm. Chem. Life Sci., 2006, 339, 238-241* * |
| BMC Complementary and Alternative Medicine (2015) 15:380* * |
| J. Agric. Food Chem. 2003, 51, 1578-1581* * |
| J. Nat. Prod. 2015, 78, 689-694* * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE102018213227A1 (en) | 2017-08-08 | 2019-02-14 | Mando Corporation | Piston pump for brake system |
| KR20190090910A (en) | 2018-01-26 | 2019-08-05 | 최윤식 | Compositions for improvement benign prostatic hyperplasia comprising bee pollen |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2017146486A1 (en) | 2017-08-31 |
| KR102043404B1 (en) | 2019-11-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP6064156B2 (en) | Deep body temperature raising agent | |
| US20010006983A1 (en) | Multicomponent biological vehicle | |
| JP2007523110A (en) | Composition for treating chronic venous disease comprising red grape leaf extract and anti-inflammatory agent | |
| KR102113193B1 (en) | Composition for improving skin conditions comprising artemisiae annuae herba, centella asiatica and green tea extract or fraction thereof and method for improving skin conditions using the same | |
| JP2003192605A (en) | Lipase inhibitant | |
| R Kubra et al. | An overview on inventions related to ginger processing and products for food and pharmaceutical applications | |
| JP5617110B2 (en) | Oral hair growth promoter | |
| KR20170100100A (en) | A pharmaceutical composition comrprising Morus alba Linne extract for preventing or treating benign prostatic hyperplasia | |
| KR101407659B1 (en) | A composition for inhibiting testosterone 5-alpha reductase | |
| JP6456997B2 (en) | Method for producing asparagus extract | |
| JP2016193882A (en) | Anti-aging agent | |
| KR20210002037A (en) | A composition for preventing, improving or treating pain comprising olive leaf and citrus pericarp extract | |
| KR101749967B1 (en) | A pharmaceutical composition comprising extract from germinated gemmule of bean for preventing or treating obesity | |
| KR102613550B1 (en) | A ginsenoside complex comprising insoluble substance curcumin | |
| KR101821925B1 (en) | A composition comprising the complex extract of Poncirus trifoliata and Cinnamommum cassia for treating or preventing allergy desmatitis | |
| KR101808944B1 (en) | Composition for preventing and treating dysmenorrhea and premature labor comprising non-polar solvent subfraction from Zingiber officinale extract | |
| KR102465346B1 (en) | A composition comprising Chrysanthemum zawadskii and Cudrania tricuspidata Bureau having anti-inflammation activity | |
| KR101919161B1 (en) | Composition for improving condition of hair and preventing hair loss | |
| KR102275268B1 (en) | Composition for relieving menopausal symptom or osteoporosis | |
| KR101738206B1 (en) | A composition comprising the complex extract of Poncirus trifoliata and Cinnamommum cassia for treating or preventing allergy desmatitis | |
| KR101420270B1 (en) | Composition comprising reacted mixture of red ginseng extract and persimmon vinegar for preventing or treating benign prostatic hyperplasia | |
| KR102020371B1 (en) | Compositions for preventing or treating pain comprising extracts of Lonicera caerulea | |
| KR20150120741A (en) | Composition for preventing or improving atopic dermatitis comprising mixture of persimmon peel, persimmon flesh, persimmon leaf and Diospyros lotus leaf as effective component | |
| JP6063499B2 (en) | Pharmaceutical composition for prevention and treatment of male infertility containing dough yellow, eggplant, agarwood, persimmon, a mixture of ginseng and honey as active ingredients | |
| KR100404455B1 (en) | Growth-promoting effects and pharmaceutical preparations containing the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AMND | Amendment | ||
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| AMND | Amendment | ||
| E601 | Decision to refuse application | ||
| AMND | Amendment | ||
| X701 | Decision to grant (after re-examination) | ||
| GRNT | Written decision to grant |